A new equine vaccine, Equivac HeV, has been developed to prevent clinical disease caused by Hendra virus in horses. The vaccine, derived from the original work of Christopher C. Broder and Katharine Bossart, is now available for use in Australia.
Researchers successfully developed a highly effective vaccine against the deadly Nipah virus, which has shown complete protection in African green monkeys with no evidence of disease. The vaccine, known as Hendra-sG, is a recombinant piece of the virus produced in the laboratory and can be used safely for human treatment.
A neutralizing human monoclonal antibody, m102.4, has been developed to protect against Hendra virus infection, showing promise as a potential treatment for severe illness and death in humans. The antibody attacks a critical component of the virus, preventing its infection of cells.
The Henry M. Jackson Foundation has awarded fellowships to three USU students, including Jeremy Gilbreath, Camden Elliott, and Kerry Whittaker, to investigate the structure and function of bacterial pathogens, Loss of Control Eating Disorder, and the relationship between positive psychosocial factors and cardiovascular health
A new study found that single-dose nevirapine can hamper the drug's effectiveness if used later to treat HIV-infected women. The WHO has revised its guidelines to advise against using nevirapine in combination with other drugs, if treatment begins fewer than 12 months after exposure.
Three USU doctoral students receive fellowships to study schistosomiasis, multiple sclerosis and tuberous sclerosis complex. The HJF program aims to develop new drug targets and treatments for these diseases.
A Phase I study has begun to evaluate a combination DNA prime/MVA vector boost vaccine regimen to protect against diverse subtypes of HIV-1. The study will enroll 92 participants and test two intramuscular delivery methods for the DNA prime, Biojector 2000 and CELLECTRA EP, to compare their effects on immune response.
Researchers have found that infectious HIV-1 virus particles can bind to the surface of red blood cells, significantly increasing their infectivity. This discovery suggests that erythrocytes may serve as a hidden reservoir for infectious HIV-1 virions.
Researchers at USU and Australian Animal Health Laboratory demonstrate effective therapy against Nipah virus using a human monoclonal antibody, m102.4. The treatment showed promising results in animal models, offering hope for preventing and treating diseases caused by the deadly viruses.
For the first time, researchers have induced antibodies that neutralize HIV-1 and simultaneously recognize both HIV-1 envelope protein and lipids. The study employed widely used, clinically acceptable, well-tolerated and relatively inexpensive generic antigen-adjuvant constituents.
The HJF has released the Military Advanced Regional Anesthesia and Analgesia Handbook, providing education on advanced battlefield regional anesthesia techniques and acute pain medicine. The handbook aims to manage the pain of combat trauma and is intended for use by deployed medical forces.
Researchers found no correlation between traditional and standardized assays, highlighting the need for a physiologically relevant platform. Clade C antibodies showed broad cross-reactivity, neutralizing multiple viruses in both formats.
Researchers at the Uniformed Services University of the Health Sciences have been awarded a $5.6 million grant to develop vaccines and treatments for Nipah and Hendra viruses. The grant will support collaboration with Australian researchers to test vaccines and therapeutics, which have shown promising results in previous studies.
Advances in sequencing and surveillance have enabled researchers to identify circulating strains of HIV-1, with subtype B prevalent in the Americas and clades A, C, and D in Sub-Saharan Africa. The study highlights the importance of viral diversity on disease progression and transmission.
Researchers at USU have developed a new HIV vaccine that induces broad-spectrum neutralizing antibodies, capable of neutralizing all 48 tested strains. The study provides encouraging results for vaccine development, showing the feasibility of eliciting cross-reactive antibodies against multiple viral strains.
Researchers at the Uniformed Services University have discovered that Deinococcus radiodurans protects itself from high doses of ionizing radiation through protein oxidation. This finding points to new avenues for radioprotection, potentially influencing cancer treatment and radioactive waste containment.
USU students Robert Anthony, Xialong Jiang, and Erika Lamb have been awarded fellowships by the Henry M. Jackson Foundation to study immune response and posttraumatic stress disorder in a neurobiological model. Their research aims to develop effective ways to combat these conditions in military service members.
A team of researchers has isolated the Ephrin-B2 cell surface protein as a functional receptor for both Hendra and Nipah viruses, shedding light on their ability to infect a wide range of hosts. The finding holds promise for developing countermeasures to prevent and treat these emerging global health threats.
Researchers have identified ERG as the first proto-oncogene commonly overexpressed in early-phase prostate cancer, providing a promising target for diagnosis and treatment. The study also found correlations between ERG expression and PSA recurrence-free survival of prostate cancer patients after radical prostatectomy.
Research reveals significant decreases in myelin lipid synthesis in mice with Canavan disease, suggesting a link between acetate deficiency and the disorder. The findings support the potential of acetate supplementation as a therapy for this devastating congenital disease.
A recent study discovered that stimulation of the CD28 receptor can regulate coreceptor expression in activated T cells, potentially preventing HIV-1 infection. This finding may lead to new therapeutic strategies for patients with HIV and other immune deficiencies.